Log in
Enquire now
‌

US Patent RE49251 Depot systems comprising glatiramer or pharmacologically acceptable salt thereof

Patent RE49251 was granted and assigned to Mapi Pharma on October, 2022 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Patent Applicant
Mapi Pharma
Mapi Pharma
0
Current Assignee
Mapi Pharma
Mapi Pharma
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
RE492510
Patent Inventor Names
Shai Rubnov0
Ehud Marom0
Date of Patent
October 18, 2022
0
Patent Application Number
172133520
Date Filed
March 26, 2021
0
Patent Primary Examiner
‌
Padmashri Ponnaluri
0
CPC Code
‌
C07K 14/001
0
‌
A61P 25/00
0
‌
A61K 38/02
0

Long acting parenteral pharmaceutical compositions comprising a therapeutically effective amount of glatiramer are provided. In particular, the present invention provides a long acting pharmaceutical composition comprising a therapeutically effective amount of glatiramer acetate in depot form suitable for administering at a medically acceptable location in a subject in need thereof. The depot form is suitable for subcutaneous or intramuscular implantation or injection.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent RE49251 Depot systems comprising glatiramer or pharmacologically acceptable salt thereof

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us